ClinicalTrials.gg
RecruitingNCT05870969dSEARCHUpdated May 23, 2023

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

An observational study in Carcinoma, Hepatocellular, Hepatitis C, Chronic and Hepatitis B, Chronic, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-23.

Sponsored by Ruijin Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
Largest of 275
20,000 · median 300
Started
2023
with 102 others
Observational
275 of 1,314
120 open now
Primary completion
2028-03
later than 460 of 560 live
Registered
822nd of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one has the largest planned enrollment of the 275 observational ones that give a count, is one of 103 that started in 2023, is one of 275 observational ones, reaches primary completion later than 460 of the 560 other live ones, and was the 822nd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

03

Conditions studied

  • Carcinoma, Hepatocellular
  • Hepatitis C, Chronic
  • Hepatitis B, Chronic
  • Cirrhosis, Liver
  • Non-Alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study mainly includes the following risk groups of liver cancer: patients with chronic hepatitis B, patients with hepatitis C, patients with liver cirrhosis, patients with metabolic dysfunction-associated fatty liver disease (MAFLD) with a liver fibrosis index F3 or above, MAFLD patients combined with abnormal glucose metabolism, and people with a family history of liver cancer in their first-degree biological relatives.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the clinical study; fully informed about the study and signed , willing to follow and capable of completing all trial procedures[17]
  2. Age: 18 to 75 years old (including the cut-offs)
  3. Subjects must meet at least one of the following criteria for enrollment.

    1. Patients diagnosed with chronic in hospital or out of hospital: persistent positive hepatitis B surface antigen (HBsAg) for 6 months or more
    2. Patients diagnosed with in hospital or out of hospital
    3. Patients diagnosed with cirrhosis in hospital or out of hospital who meet at least one of the following criteria.

      1. Liver showing cirrhosis (Ishak score ≥5 or Metavir score = 4);
      2. Liver stiffness measurement (LSM) using FibroScan® (Echosens™, Paris, France) ≥12.0 kPa when TB was normal and ≤ 40 IU/mL, or LSM ≥ 17.0 kPa when TB was normal and ALT \< 200 IU/mL;
      3. Abdominal imaging results showing characteristic of cirrhosis (results showing coarse liver echotexture or nodular, parenchymal, or morphological abnormalities and signs of gastroesophageal varices);
      4. APRI ≥ 2.0;
      5. FIB-4 ≥ 3.25
    4. Patients diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) in hospital or out of hospital who have a liver fibrosis score of F3 or higher according to transient elastography, i.e., FibroScan® Liver Stiffness Measurement (LSM) ≥ 10 kPa or the corresponding FibroTouch® measurement threshold[18].

      • MAFLD diagnosis requires diagnosis of >5% fat accumulation in liver through either FibroScan® CAP measurements, or similar parameter, or liver biopsy, and in combination with one of the following three conditions: overweight/obesity ( >23 kg/m2), type 2 diabetes, or metabolic dysfunction.
    5. Patients diagnosed with MAFLD combined with abnormal glucose metabolism[19]

      • Abnormal glucose metabolism is defined as type 2 diabetes, or prediabetes, i.e. fasting blood glucose 5.6-6.9 mmol/L, or 2h postprandial blood glucose 7.8-11.0 mmol/L, or 5.7%-6.4%
    6. Subjects with a family history of liver cancer in their first-degree biological relatives.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from the study:

  1. Age \<18 years or >75 years
  2. Patients who have been diagnosed with liver cancer before enrollment
  3. Patients with severe mental illness or cognitive impairment
  4. Patients who are pregnant or lactating, or preparing to become pregnant
  5. Patients who have participated in other clinical trials or are participating in other clinical trials within 3 months prior to initiation of study treatment
  6. According to the doctor's judgment, the possibility of the subject being included is low (including inability to understand the project requirements , poor compliance, infirmity, inability to ensure that the protocol can be implemented as required, etc.), or the doctor determines that the subject has any other factors that are not suitable for this study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with very high risk for HCC according local guideline

    Behavioral: Liver cancer surveillance every 3 months

  • Patients with high risk for HCC according local guideline

    Behavioral: Liver cancer surveillance every 3 months

  • Patients with medium risk for HCC according local guideline

    Behavioral: Liver cancer surveillance every 6 months

  • Patients with low risk for HCC according local guideline

    Behavioral: Liver cancer surveillance annually

Interventions

  • BehavioralLiver cancer surveillance every 3 months

    Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

  • BehavioralLiver cancer surveillance every 6 months

    Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

  • BehavioralLiver cancer surveillance annually

    Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

06

What researchers measure

Primary outcomes

  1. Early diagnosis rate of HCC patients

    The proportion of patients who are first diagnosed with HCC at early stage to all the patients diagnosed as liver cancer in the study, from the start of the study to the completion of follow-up. Early diagnosis is defined as the patient with stage CNLC Ia, Ib and IIa.

    Time frame: Follow up up to three years for HCC occurance.

Secondary outcomes

  1. Proportion of subjects with regular follow-up

    Regular follow-up is defined as the average difference between the actual treatment time and the theoretical treatment time equal or less than 1/3 * Actual visit interval: actual visit date - previous visit date ② Theoretical visit interval: theoretical visit date (the date that physician advise to return to hospital for visit) - previous visit date ③ Follow-up compliance = (②-①)/② ④ Patient with regular follow-up is defined as the patient whose mean follow-up compliance is equal to, or less than 1/3 * The compliance of the study is defined as the proportion of subjects with regular follow-up to all subjects in the study.

    Time frame: Four years collectively after the study started

  2. The distribution of risk stratification of liver cancer in subjects at initial screening

    The proportion of very high-risk, high-risk, medium-risk, and low-risk subjects to the whole subject population

    Time frame: Initial screening after enrollment

  3. The distribution of risk stratification of liver cancer in subjects at the last follow-up visit or at the time of diagnosis of liver cancer

    The proportion of very high-risk, high-risk, medium-risk and low-risk subjects to the whole subject population

    Time frame: Last follow-up visit or at the time of diagnosis of liver cancer up to three years of follow-up

  4. Pooled 3-year cumulative incidence of liver cancer

    Time frame: Follow up up to 3 years

  5. The early diagnosis rate of liver cancer in each subject category according to the risk stratification at initial screening

    The early diagnosis rate of liver cancer of subjects with very high-risk, high-risk, medium-risk, and low-risk at initial screening, respectively

    Time frame: Initial screening after enrollment

  6. The 3-year cumulative incidence of liver cancer in each subject category according to the risk stratification at the time of initial diagnosis

    The 3-year cumulative incidence of liver cancer for subjects with very high-risk, high-risk, medium-risk, and low-risk, respectively

    Time frame: Four years collectively after the study started

Other outcomes

  1. The number of patients first diagnosed with liver cancer and the annual incidence rate

    Time frame: Four years collectively after the study started

  2. The number of patients first diagnosed with liver cancer and the annual incidence rate within each risk category

    Time frame: Four years collectively after the study started

  3. The distribution of the CNLC staging of patients diagnosed as liver cancer first from the start of the study to the completion of follow-up

    Time frame: Four years collectively after the study started

  4. The 3-year cumulative incidence of liver cancer in each disease subgroup

    The disease types include but are not limited to hepatitis B, hepatitis C, cirrhosis, MAFLD

    Time frame: Follow up up to 3 years

  5. Early diagnosis rate of HCC in each disease subgroup

    The disease types include but are not limited to hepatitis B, hepatitis C, cirrhosis, MAFLD; early diagnosis of HCC is defined as the patient with stage CNLC Ia, Ib and IIa

    Time frame: Four years collectively after the study started

  6. The compliance rate of each risk group defined at the initial risk stratification

    The compliance rates for subjects with very high-risk, high-risk, medium-risk, and low-risk; the compliance rate is defined the same as above

    Time frame: Four years collectively after the study started

07

Study locations

1 of 1 sites recruiting
  • Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai, China
    Recruiting
    • Qing Xie, MD, PhD. · Contactxieqingrjh@163.com · 0086-021-64370045
    • Honglian Gui, MD,PhD · Contactlillian_ghl@163.com · 0086-021-64370045
    • Qing Xie, MD, PhD. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 60 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2023
First posted
May 23, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
May 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05870969
Lead sponsor
Ruijin Hospital
Responsible party
Qing XIe (Director of Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Ruijin Hospital) — Principal investigator
First posted
May 23, 2023
Start date
Mar 1, 2023
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
May 23, 2023

Study contacts

Qing Xie, MD
Contact
xieqingrjh@163.com
0086-021-64370045 ext. 680403
Honglian Gui, MD,PhD
Contact
lillian_ghl@163.com
0086-021-64370045 ext. 680419

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion